Pliant Therapeutics Inc [PLRX] attracts people because of its fundamentals

Pliant Therapeutics Inc (NASDAQ:PLRX) shares traded 12.59% higher at $1.52 on Wall Street last session.

PLRX stock price is now -82.85% away from the 50-day moving average and -87.21% away from the 200-day moving average. The market capitalization of the company currently stands at $93.08M.

, while ‘Stifel’ rates the stock as ‘Hold’

In other news, Coulie Bernard, President and CEO sold 52,419 shares of the company’s stock on Jan 17 ’25. The stock was sold for $587,150 at an average price of $11.20. Upon completion of the transaction, the President and CEO now directly owns 430,517 shares in the company, valued at $0.65 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 17 ’25, Chief Financial Officer Cummings Keith Lamont sold 20,148 shares of the business’s stock. A total of $225,680 was realized by selling the stock at an average price of $11.20. This leaves the insider owning 262,608 shares of the company worth $0.4 million. A total of 13.46% of the company’s stock is owned by insiders.

During the past 12 months, Pliant Therapeutics Inc has had a low of $1.27 and a high of $16.73. As of last week, the company has a debt-to-equity ratio of 0.20, a current ratio of 10.91, and a quick ratio of 10.91.

The company reported revenue of $53.32 million for the quarter, compared to $47.04 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 13.36 percent.

Related Posts

Fosters Research
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.